Analysts Set Expectations for Atossa Genetics Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Atossa Genetics to ($0.07) per share, down from the previous estimate of ($0.06), indicating a weaker outlook for the company.
• Despite lowered earnings expectations, Craig Hallum upgraded Atossa Genetics to a "strong-buy" rating with a target price of $4.00, while Ascendiant Capital Markets raised their target price from $7.25 to $7.50.
• Atossa Genetics shares traded at $0.79, reflecting a market capitalization of $102.04 million and showing a one-year price range between $0.55 and $1.66.

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) - HC Wainwright cut their Q3 2025 earnings per share estimates for Atossa Genetics in a report issued on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.07) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Atossa Genetics' current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics' FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.23) EPS and FY2029 earnings at ($0.18) EPS.

Several other research firms have also issued reports on ATOS. Craig Hallum upgraded Atossa Genetics to a "strong-buy" rating and set a $4.00 target price on the stock in a report on Thursday, June 5th. Ascendiant Capital Markets upped their target price on Atossa Genetics from $7.25 to $7.50 and gave the stock a "buy" rating in a report on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat.com, Atossa Genetics presently has a consensus rating of "Buy" and an average target price of $6.17.

Atossa Genetics Stock Performance

ATOS traded down $0.0115 on Friday, hitting $0.7385. 478,760 shares of the company were exchanged, compared to its average volume of 870,348. Atossa Genetics has a 12 month low of $0.5526 and a 12 month high of $1.66. The company has a market cap of $95.39 million, a PE ratio of -3.21 and a beta of 0.92. The stock's fifty day moving average is $0.84 and its 200-day moving average is $0.79.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01).

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics during the second quarter worth approximately $26,000. Bank of America Corp DE increased its position in Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock worth $83,000 after buying an additional 35,629 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in Atossa Genetics during the second quarter worth approximately $2,468,000. Jane Street Group LLC acquired a new position in Atossa Genetics during the second quarter worth approximately $381,000. Finally, Qube Research & Technologies Ltd increased its position in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company's stock worth $346,000 after buying an additional 325,340 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company's stock.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.